nodes	percent_of_prediction	percent_of_DWPC	metapath
Naproxen—PTGS2—bone cancer	0.328	1	CbGaD
Naproxen—AKR1C3—Doxorubicin—bone cancer	0.203	0.431	CbGbCtD
Naproxen—UGT2B7—Epirubicin—bone cancer	0.12	0.253	CbGbCtD
Naproxen—PTGS2—Cisplatin—bone cancer	0.0492	0.104	CbGbCtD
Naproxen—SLCO1A2—Methotrexate—bone cancer	0.039	0.0827	CbGbCtD
Naproxen—SLC22A6—Methotrexate—bone cancer	0.0237	0.0502	CbGbCtD
Naproxen—ALB—Methotrexate—bone cancer	0.0202	0.0427	CbGbCtD
Naproxen—CYP2C9—Cisplatin—bone cancer	0.0167	0.0355	CbGbCtD
Naproxen—Nabumetone—PTGS2—bone cancer	0.000831	0.23	CrCbGaD
Naproxen—Carprofen—PTGS2—bone cancer	0.000793	0.219	CrCbGaD
Naproxen—CYP2C9—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000629	0.0161	CbGpPWpGaD
Naproxen—ALB—Folate Metabolism—FOLR1—bone cancer	0.000613	0.0157	CbGpPWpGaD
Naproxen—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—bone cancer	0.000601	0.0154	CbGpPWpGaD
Naproxen—CYP1A2—Aflatoxin B1 metabolism—CYP3A4—bone cancer	0.000601	0.0154	CbGpPWpGaD
Naproxen—CYP1A2—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.000537	0.0138	CbGpPWpGaD
Naproxen—Suprofen—PTGS2—bone cancer	0.00049	0.135	CrCbGaD
Naproxen—UGT1A1—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000486	0.0125	CbGpPWpGaD
Naproxen—Fenoprofen—PTGS2—bone cancer	0.000422	0.117	CrCbGaD
Naproxen—CYP2C8—Xenobiotics—CYP3A4—bone cancer	0.000373	0.00957	CbGpPWpGaD
Naproxen—CYP2C8—Tamoxifen metabolism—CYP3A4—bone cancer	0.000359	0.00921	CbGpPWpGaD
Naproxen—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL3—bone cancer	0.00034	0.00874	CbGpPWpGaD
Naproxen—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—bone cancer	0.00034	0.00874	CbGpPWpGaD
Naproxen—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00034	0.00872	CbGpPWpGaD
Naproxen—CYP2C8—Metapathway biotransformation—CYP4V2—bone cancer	0.000333	0.00854	CbGpPWpGaD
Naproxen—Indomethacin—PTGS2—bone cancer	0.000311	0.0861	CrCbGaD
Naproxen—CYP1A2—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.00031	0.00796	CbGpPWpGaD
Naproxen—CYP2C9—Xenobiotics—CYP3A4—bone cancer	0.000304	0.00779	CbGpPWpGaD
Naproxen—PTGS2—Signaling mediated by p38-alpha and p38-beta—ATF1—bone cancer	0.0003	0.00771	CbGpPWpGaD
Naproxen—CYP2C9—Tamoxifen metabolism—CYP3A4—bone cancer	0.000292	0.00749	CbGpPWpGaD
Naproxen—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.00029	0.00746	CbGpPWpGaD
Naproxen—AKR1C3—Arachidonic acid metabolism—PTGS2—bone cancer	0.000282	0.00725	CbGpPWpGaD
Naproxen—CYP1A2—Estrogen metabolism—CYP3A4—bone cancer	0.000282	0.00724	CbGpPWpGaD
Naproxen—Flurbiprofen—PTGS2—bone cancer	0.000275	0.0761	CrCbGaD
Naproxen—CYP2C9—Metapathway biotransformation—CYP4V2—bone cancer	0.000271	0.00695	CbGpPWpGaD
Naproxen—CYP1A2—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.00027	0.00694	CbGpPWpGaD
Naproxen—PTGS1—Overview of nanoparticle effects—PTGS2—bone cancer	0.000267	0.00684	CbGpPWpGaD
Naproxen—CYP1A2—Xenobiotics—CYP3A4—bone cancer	0.000259	0.00666	CbGpPWpGaD
Naproxen—ALB—Binding and Uptake of Ligands by Scavenger Receptors—SPARC—bone cancer	0.000252	0.00646	CbGpPWpGaD
Naproxen—CYP1A2—Tamoxifen metabolism—CYP3A4—bone cancer	0.000249	0.0064	CbGpPWpGaD
Naproxen—Ketoprofen—PTGS2—bone cancer	0.000249	0.0689	CrCbGaD
Naproxen—Ibuprofen—PTGS2—bone cancer	0.000245	0.0678	CrCbGaD
Naproxen—AKR1C3—Metapathway biotransformation—CYP3A4—bone cancer	0.000234	0.00601	CbGpPWpGaD
Naproxen—CYP1A2—Metapathway biotransformation—CYP4V2—bone cancer	0.000231	0.00594	CbGpPWpGaD
Naproxen—UGT2B7—Phase II conjugation—GSTP1—bone cancer	0.000228	0.00585	CbGpPWpGaD
Naproxen—PTGS1—Eicosanoid Synthesis—PTGS2—bone cancer	0.000221	0.00568	CbGpPWpGaD
Naproxen—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL3—bone cancer	0.00022	0.00565	CbGpPWpGaD
Naproxen—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—bone cancer	0.000219	0.00562	CbGpPWpGaD
Naproxen—CYP2C9—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000208	0.00535	CbGpPWpGaD
Naproxen—AKR1C3—Metapathway biotransformation—GSTP1—bone cancer	0.0002	0.00514	CbGpPWpGaD
Naproxen—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000199	0.0051	CbGpPWpGaD
Naproxen—PTGS1—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000194	0.00499	CbGpPWpGaD
Naproxen—UGT1A1—Phase II conjugation—GSTP1—bone cancer	0.000185	0.00475	CbGpPWpGaD
Naproxen—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—bone cancer	0.000185	0.00475	CbGpPWpGaD
Naproxen—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.00017	0.00436	CbGpPWpGaD
Naproxen—ALB—Folate Metabolism—DHFR—bone cancer	0.000168	0.00432	CbGpPWpGaD
Naproxen—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—DHFR—bone cancer	0.000167	0.00428	CbGpPWpGaD
Naproxen—UGT2B7—Biological oxidations—CYP3A4—bone cancer	0.000156	0.004	CbGpPWpGaD
Naproxen—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000155	0.00398	CbGpPWpGaD
Naproxen—UGT2B7—Metapathway biotransformation—CYP3A4—bone cancer	0.000154	0.00395	CbGpPWpGaD
Naproxen—CYP2C8—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000153	0.00392	CbGpPWpGaD
Naproxen—UGT2B7—NRF2 pathway—GSTP1—bone cancer	0.000152	0.0039	CbGpPWpGaD
Naproxen—UGT2B7—NRF2 pathway—TGFBR2—bone cancer	0.000152	0.0039	CbGpPWpGaD
Naproxen—ALB—Platelet degranulation—SPARC—bone cancer	0.000148	0.00379	CbGpPWpGaD
Naproxen—CYP1A2—Estrogen Receptor Pathway—JUN—bone cancer	0.000146	0.00375	CbGpPWpGaD
Naproxen—UGT1A1—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.000145	0.00373	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—NDUFA12—bone cancer	0.000142	0.00365	CbGpPWpGaD
Naproxen—ALB—Response to elevated platelet cytosolic Ca2+—SPARC—bone cancer	0.000141	0.00361	CbGpPWpGaD
Naproxen—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CDK4—bone cancer	0.000137	0.0035	CbGpPWpGaD
Naproxen—PTGS2—Calcium signaling in the CD4+ TCR pathway—JUN—bone cancer	0.000136	0.00349	CbGpPWpGaD
Naproxen—UGT2B7—Biological oxidations—GSTP1—bone cancer	0.000133	0.00342	CbGpPWpGaD
Naproxen—CYP1A2—Tryptophan metabolism—CYP3A4—bone cancer	0.000133	0.00342	CbGpPWpGaD
Naproxen—UGT2B7—Metapathway biotransformation—GSTP1—bone cancer	0.000131	0.00337	CbGpPWpGaD
Naproxen—PTGS2—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000127	0.00326	CbGpPWpGaD
Naproxen—UGT1A1—Biological oxidations—CYP3A4—bone cancer	0.000127	0.00325	CbGpPWpGaD
Naproxen—Pneumonia—Doxorubicin—bone cancer	0.000126	0.000805	CcSEcCtD
Naproxen—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000126	0.00324	CbGpPWpGaD
Naproxen—Drowsiness—Doxorubicin—bone cancer	0.000126	0.0008	CcSEcCtD
Naproxen—Visual impairment—Methotrexate—bone cancer	0.000126	0.0008	CcSEcCtD
Naproxen—CYP2C8—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000126	0.00322	CbGpPWpGaD
Naproxen—UGT1A1—Metapathway biotransformation—CYP3A4—bone cancer	0.000125	0.00321	CbGpPWpGaD
Naproxen—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.000125	0.000794	CcSEcCtD
Naproxen—CYP2C9—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000124	0.00319	CbGpPWpGaD
Naproxen—Hypersensitivity—Cisplatin—bone cancer	0.000124	0.000792	CcSEcCtD
Naproxen—Renal failure—Doxorubicin—bone cancer	0.000124	0.000787	CcSEcCtD
Naproxen—UGT1A1—NRF2 pathway—TGFBR2—bone cancer	0.000123	0.00317	CbGpPWpGaD
Naproxen—UGT1A1—NRF2 pathway—GSTP1—bone cancer	0.000123	0.00317	CbGpPWpGaD
Naproxen—Erythema multiforme—Methotrexate—bone cancer	0.000123	0.000785	CcSEcCtD
Naproxen—Neuropathy peripheral—Doxorubicin—bone cancer	0.000123	0.000785	CcSEcCtD
Naproxen—PTGS1—Arachidonic acid metabolism—PTGS2—bone cancer	0.000123	0.00316	CbGpPWpGaD
Naproxen—Haemoglobin—Epirubicin—bone cancer	0.000123	0.000781	CcSEcCtD
Naproxen—Stomatitis—Doxorubicin—bone cancer	0.000123	0.00078	CcSEcCtD
Naproxen—Jaundice—Doxorubicin—bone cancer	0.000123	0.00078	CcSEcCtD
Naproxen—Rhinitis—Epirubicin—bone cancer	0.000122	0.000779	CcSEcCtD
Naproxen—Urinary tract infection—Doxorubicin—bone cancer	0.000122	0.000778	CcSEcCtD
Naproxen—Conjunctivitis—Doxorubicin—bone cancer	0.000122	0.000778	CcSEcCtD
Naproxen—Haemorrhage—Epirubicin—bone cancer	0.000122	0.000777	CcSEcCtD
Naproxen—Hepatitis—Epirubicin—bone cancer	0.000122	0.000777	CcSEcCtD
Naproxen—Eye disorder—Methotrexate—bone cancer	0.000122	0.000776	CcSEcCtD
Naproxen—Tinnitus—Methotrexate—bone cancer	0.000122	0.000774	CcSEcCtD
Naproxen—Asthenia—Cisplatin—bone cancer	0.000121	0.000771	CcSEcCtD
Naproxen—Pharyngitis—Epirubicin—bone cancer	0.000121	0.000771	CcSEcCtD
Naproxen—Cardiac disorder—Methotrexate—bone cancer	0.000121	0.00077	CcSEcCtD
Naproxen—Sweating—Doxorubicin—bone cancer	0.000121	0.000767	CcSEcCtD
Naproxen—Urinary tract disorder—Epirubicin—bone cancer	0.00012	0.000767	CcSEcCtD
Naproxen—Oedema peripheral—Epirubicin—bone cancer	0.00012	0.000765	CcSEcCtD
Naproxen—Haematuria—Doxorubicin—bone cancer	0.00012	0.000763	CcSEcCtD
Naproxen—Connective tissue disorder—Epirubicin—bone cancer	0.00012	0.000763	CcSEcCtD
Naproxen—Urethral disorder—Epirubicin—bone cancer	0.00012	0.000761	CcSEcCtD
Naproxen—Hepatobiliary disease—Doxorubicin—bone cancer	0.000119	0.000757	CcSEcCtD
Naproxen—Epistaxis—Doxorubicin—bone cancer	0.000119	0.000755	CcSEcCtD
Naproxen—Angiopathy—Methotrexate—bone cancer	0.000118	0.000753	CcSEcCtD
Naproxen—Sinusitis—Doxorubicin—bone cancer	0.000118	0.000751	CcSEcCtD
Naproxen—AKR1C3—Metabolism—NT5C3A—bone cancer	0.000118	0.00302	CbGpPWpGaD
Naproxen—Immune system disorder—Methotrexate—bone cancer	0.000118	0.00075	CcSEcCtD
Naproxen—Visual impairment—Epirubicin—bone cancer	0.000118	0.000748	CcSEcCtD
Naproxen—Mediastinal disorder—Methotrexate—bone cancer	0.000117	0.000748	CcSEcCtD
Naproxen—Agranulocytosis—Doxorubicin—bone cancer	0.000117	0.000747	CcSEcCtD
Naproxen—PTGS2—Signaling mediated by p38-alpha and p38-beta—JUN—bone cancer	0.000117	0.003	CbGpPWpGaD
Naproxen—Chills—Methotrexate—bone cancer	0.000117	0.000745	CcSEcCtD
Naproxen—Diarrhoea—Cisplatin—bone cancer	0.000115	0.000735	CcSEcCtD
Naproxen—Erythema multiforme—Epirubicin—bone cancer	0.000115	0.000734	CcSEcCtD
Naproxen—Alopecia—Methotrexate—bone cancer	0.000115	0.000733	CcSEcCtD
Naproxen—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	0.000114	0.00293	CbGpPWpGaD
Naproxen—Mental disorder—Methotrexate—bone cancer	0.000114	0.000727	CcSEcCtD
Naproxen—Eye disorder—Epirubicin—bone cancer	0.000114	0.000726	CcSEcCtD
Naproxen—Tinnitus—Epirubicin—bone cancer	0.000114	0.000724	CcSEcCtD
Naproxen—Erythema—Methotrexate—bone cancer	0.000113	0.000722	CcSEcCtD
Naproxen—Malnutrition—Methotrexate—bone cancer	0.000113	0.000722	CcSEcCtD
Naproxen—Haemoglobin—Doxorubicin—bone cancer	0.000113	0.000722	CcSEcCtD
Naproxen—Cardiac disorder—Epirubicin—bone cancer	0.000113	0.000721	CcSEcCtD
Naproxen—Rhinitis—Doxorubicin—bone cancer	0.000113	0.00072	CcSEcCtD
Naproxen—Hepatitis—Doxorubicin—bone cancer	0.000113	0.000719	CcSEcCtD
Naproxen—Haemorrhage—Doxorubicin—bone cancer	0.000113	0.000719	CcSEcCtD
Naproxen—Pharyngitis—Doxorubicin—bone cancer	0.000112	0.000713	CcSEcCtD
Naproxen—Urinary tract disorder—Doxorubicin—bone cancer	0.000111	0.00071	CcSEcCtD
Naproxen—Oedema peripheral—Doxorubicin—bone cancer	0.000111	0.000708	CcSEcCtD
Naproxen—Connective tissue disorder—Doxorubicin—bone cancer	0.000111	0.000706	CcSEcCtD
Naproxen—Angiopathy—Epirubicin—bone cancer	0.000111	0.000705	CcSEcCtD
Naproxen—Urethral disorder—Doxorubicin—bone cancer	0.000111	0.000704	CcSEcCtD
Naproxen—Immune system disorder—Epirubicin—bone cancer	0.00011	0.000701	CcSEcCtD
Naproxen—Mediastinal disorder—Epirubicin—bone cancer	0.00011	0.0007	CcSEcCtD
Naproxen—Chills—Epirubicin—bone cancer	0.000109	0.000697	CcSEcCtD
Naproxen—Arrhythmia—Epirubicin—bone cancer	0.000109	0.000694	CcSEcCtD
Naproxen—Visual impairment—Doxorubicin—bone cancer	0.000109	0.000692	CcSEcCtD
Naproxen—UGT1A1—Biological oxidations—GSTP1—bone cancer	0.000108	0.00278	CbGpPWpGaD
Naproxen—Alopecia—Epirubicin—bone cancer	0.000108	0.000686	CcSEcCtD
Naproxen—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000108	0.00276	CbGpPWpGaD
Naproxen—Vomiting—Cisplatin—bone cancer	0.000107	0.000683	CcSEcCtD
Naproxen—Vision blurred—Methotrexate—bone cancer	0.000107	0.000681	CcSEcCtD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—WT1—bone cancer	0.000107	0.00274	CbGpPWpGaD
Naproxen—Mental disorder—Epirubicin—bone cancer	0.000107	0.00068	CcSEcCtD
Naproxen—UGT1A1—Metapathway biotransformation—GSTP1—bone cancer	0.000107	0.00274	CbGpPWpGaD
Naproxen—Erythema multiforme—Doxorubicin—bone cancer	0.000107	0.000679	CcSEcCtD
Naproxen—Rash—Cisplatin—bone cancer	0.000106	0.000677	CcSEcCtD
Naproxen—Dermatitis—Cisplatin—bone cancer	0.000106	0.000677	CcSEcCtD
Naproxen—CYP1A2—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000106	0.00273	CbGpPWpGaD
Naproxen—Erythema—Epirubicin—bone cancer	0.000106	0.000676	CcSEcCtD
Naproxen—Malnutrition—Epirubicin—bone cancer	0.000106	0.000676	CcSEcCtD
Naproxen—Eye disorder—Doxorubicin—bone cancer	0.000105	0.000672	CcSEcCtD
Naproxen—Ill-defined disorder—Methotrexate—bone cancer	0.000105	0.00067	CcSEcCtD
Naproxen—Tinnitus—Doxorubicin—bone cancer	0.000105	0.00067	CcSEcCtD
Naproxen—Anaemia—Methotrexate—bone cancer	0.000105	0.000668	CcSEcCtD
Naproxen—Cardiac disorder—Doxorubicin—bone cancer	0.000105	0.000667	CcSEcCtD
Naproxen—Flatulence—Epirubicin—bone cancer	0.000105	0.000666	CcSEcCtD
Naproxen—Tension—Epirubicin—bone cancer	0.000104	0.000663	CcSEcCtD
Naproxen—SLCO1A2—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000104	0.00267	CbGpPWpGaD
Naproxen—PTGS1—Biological oxidations—CYP3A4—bone cancer	0.000103	0.00265	CbGpPWpGaD
Naproxen—Nervousness—Epirubicin—bone cancer	0.000103	0.000657	CcSEcCtD
Naproxen—Angiopathy—Doxorubicin—bone cancer	0.000102	0.000652	CcSEcCtD
Naproxen—Malaise—Methotrexate—bone cancer	0.000102	0.000651	CcSEcCtD
Naproxen—CYP2C9—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000102	0.00262	CbGpPWpGaD
Naproxen—Muscle spasms—Epirubicin—bone cancer	0.000102	0.00065	CcSEcCtD
Naproxen—Immune system disorder—Doxorubicin—bone cancer	0.000102	0.000649	CcSEcCtD
Naproxen—Vertigo—Methotrexate—bone cancer	0.000102	0.000649	CcSEcCtD
Naproxen—Mediastinal disorder—Doxorubicin—bone cancer	0.000102	0.000648	CcSEcCtD
Naproxen—Leukopenia—Methotrexate—bone cancer	0.000102	0.000647	CcSEcCtD
Naproxen—Chills—Doxorubicin—bone cancer	0.000101	0.000645	CcSEcCtD
Naproxen—Arrhythmia—Doxorubicin—bone cancer	0.000101	0.000642	CcSEcCtD
Naproxen—Nausea—Cisplatin—bone cancer	0.0001	0.000638	CcSEcCtD
Naproxen—Vision blurred—Epirubicin—bone cancer	0.0001	0.000637	CcSEcCtD
Naproxen—Alopecia—Doxorubicin—bone cancer	9.97e-05	0.000635	CcSEcCtD
Naproxen—Cough—Methotrexate—bone cancer	9.9e-05	0.00063	CcSEcCtD
Naproxen—Mental disorder—Doxorubicin—bone cancer	9.89e-05	0.00063	CcSEcCtD
Naproxen—Ill-defined disorder—Epirubicin—bone cancer	9.85e-05	0.000627	CcSEcCtD
Naproxen—Convulsion—Methotrexate—bone cancer	9.83e-05	0.000626	CcSEcCtD
Naproxen—Erythema—Doxorubicin—bone cancer	9.83e-05	0.000626	CcSEcCtD
Naproxen—Malnutrition—Doxorubicin—bone cancer	9.83e-05	0.000626	CcSEcCtD
Naproxen—Anaemia—Epirubicin—bone cancer	9.82e-05	0.000625	CcSEcCtD
Naproxen—SLC22A6—Transmembrane transport of small molecules—TUBB4B—bone cancer	9.78e-05	0.00251	CbGpPWpGaD
Naproxen—Flatulence—Doxorubicin—bone cancer	9.68e-05	0.000616	CcSEcCtD
Naproxen—Arthralgia—Methotrexate—bone cancer	9.66e-05	0.000615	CcSEcCtD
Naproxen—Myalgia—Methotrexate—bone cancer	9.66e-05	0.000615	CcSEcCtD
Naproxen—Chest pain—Methotrexate—bone cancer	9.66e-05	0.000615	CcSEcCtD
Naproxen—Tension—Doxorubicin—bone cancer	9.64e-05	0.000614	CcSEcCtD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	9.59e-05	0.000611	CcSEcCtD
Naproxen—Malaise—Epirubicin—bone cancer	9.58e-05	0.00061	CcSEcCtD
Naproxen—Discomfort—Methotrexate—bone cancer	9.55e-05	0.000608	CcSEcCtD
Naproxen—Nervousness—Doxorubicin—bone cancer	9.54e-05	0.000608	CcSEcCtD
Naproxen—Vertigo—Epirubicin—bone cancer	9.54e-05	0.000607	CcSEcCtD
Naproxen—Syncope—Epirubicin—bone cancer	9.52e-05	0.000606	CcSEcCtD
Naproxen—Leukopenia—Epirubicin—bone cancer	9.51e-05	0.000605	CcSEcCtD
Naproxen—Muscle spasms—Doxorubicin—bone cancer	9.45e-05	0.000601	CcSEcCtD
Naproxen—Palpitations—Epirubicin—bone cancer	9.39e-05	0.000597	CcSEcCtD
Naproxen—UGT2B7—Metabolism—NDUFA12—bone cancer	9.34e-05	0.0024	CbGpPWpGaD
Naproxen—Confusional state—Methotrexate—bone cancer	9.34e-05	0.000594	CcSEcCtD
Naproxen—Loss of consciousness—Epirubicin—bone cancer	9.33e-05	0.000594	CcSEcCtD
Naproxen—Cough—Epirubicin—bone cancer	9.27e-05	0.00059	CcSEcCtD
Naproxen—Anaphylactic shock—Methotrexate—bone cancer	9.26e-05	0.00059	CcSEcCtD
Naproxen—Vision blurred—Doxorubicin—bone cancer	9.26e-05	0.00059	CcSEcCtD
Naproxen—Convulsion—Epirubicin—bone cancer	9.2e-05	0.000586	CcSEcCtD
Naproxen—Infection—Methotrexate—bone cancer	9.2e-05	0.000586	CcSEcCtD
Naproxen—Hypertension—Epirubicin—bone cancer	9.17e-05	0.000584	CcSEcCtD
Naproxen—Ill-defined disorder—Doxorubicin—bone cancer	9.12e-05	0.00058	CcSEcCtD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	9.09e-05	0.00233	CbGpPWpGaD
Naproxen—Nervous system disorder—Methotrexate—bone cancer	9.08e-05	0.000578	CcSEcCtD
Naproxen—Anaemia—Doxorubicin—bone cancer	9.08e-05	0.000578	CcSEcCtD
Naproxen—Thrombocytopenia—Methotrexate—bone cancer	9.07e-05	0.000577	CcSEcCtD
Naproxen—Myalgia—Epirubicin—bone cancer	9.04e-05	0.000576	CcSEcCtD
Naproxen—Arthralgia—Epirubicin—bone cancer	9.04e-05	0.000576	CcSEcCtD
Naproxen—Chest pain—Epirubicin—bone cancer	9.04e-05	0.000576	CcSEcCtD
Naproxen—Anxiety—Epirubicin—bone cancer	9.01e-05	0.000574	CcSEcCtD
Naproxen—Skin disorder—Methotrexate—bone cancer	9e-05	0.000573	CcSEcCtD
Naproxen—SLCO1A2—Transmembrane transport of small molecules—TUBB2A—bone cancer	8.98e-05	0.00231	CbGpPWpGaD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	8.98e-05	0.000572	CcSEcCtD
Naproxen—Hyperhidrosis—Methotrexate—bone cancer	8.95e-05	0.00057	CcSEcCtD
Naproxen—Discomfort—Epirubicin—bone cancer	8.93e-05	0.000569	CcSEcCtD
Naproxen—Malaise—Doxorubicin—bone cancer	8.86e-05	0.000564	CcSEcCtD
Naproxen—Dry mouth—Epirubicin—bone cancer	8.84e-05	0.000563	CcSEcCtD
Naproxen—PTGS1—Biological oxidations—GSTP1—bone cancer	8.83e-05	0.00227	CbGpPWpGaD
Naproxen—Vertigo—Doxorubicin—bone cancer	8.83e-05	0.000562	CcSEcCtD
Naproxen—Anorexia—Methotrexate—bone cancer	8.83e-05	0.000562	CcSEcCtD
Naproxen—Syncope—Doxorubicin—bone cancer	8.81e-05	0.000561	CcSEcCtD
Naproxen—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—JUN—bone cancer	8.8e-05	0.00226	CbGpPWpGaD
Naproxen—Leukopenia—Doxorubicin—bone cancer	8.8e-05	0.00056	CcSEcCtD
Naproxen—Confusional state—Epirubicin—bone cancer	8.74e-05	0.000556	CcSEcCtD
Naproxen—CYP1A2—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	8.73e-05	0.00224	CbGpPWpGaD
Naproxen—Palpitations—Doxorubicin—bone cancer	8.68e-05	0.000553	CcSEcCtD
Naproxen—Anaphylactic shock—Epirubicin—bone cancer	8.67e-05	0.000552	CcSEcCtD
Naproxen—Oedema—Epirubicin—bone cancer	8.67e-05	0.000552	CcSEcCtD
Naproxen—Hypotension—Methotrexate—bone cancer	8.65e-05	0.000551	CcSEcCtD
Naproxen—Loss of consciousness—Doxorubicin—bone cancer	8.64e-05	0.00055	CcSEcCtD
Naproxen—Infection—Epirubicin—bone cancer	8.61e-05	0.000548	CcSEcCtD
Naproxen—Cough—Doxorubicin—bone cancer	8.57e-05	0.000546	CcSEcCtD
Naproxen—Shock—Epirubicin—bone cancer	8.53e-05	0.000543	CcSEcCtD
Naproxen—Convulsion—Doxorubicin—bone cancer	8.51e-05	0.000542	CcSEcCtD
Naproxen—Nervous system disorder—Epirubicin—bone cancer	8.5e-05	0.000541	CcSEcCtD
Naproxen—Thrombocytopenia—Epirubicin—bone cancer	8.49e-05	0.00054	CcSEcCtD
Naproxen—PTGS2—C-MYB transcription factor network—KIT—bone cancer	8.49e-05	0.00218	CbGpPWpGaD
Naproxen—Hypertension—Doxorubicin—bone cancer	8.48e-05	0.00054	CcSEcCtD
Naproxen—Tachycardia—Epirubicin—bone cancer	8.46e-05	0.000538	CcSEcCtD
Naproxen—SLC22A6—Transmembrane transport of small molecules—TUBB2A—bone cancer	8.44e-05	0.00217	CbGpPWpGaD
Naproxen—Musculoskeletal discomfort—Methotrexate—bone cancer	8.44e-05	0.000537	CcSEcCtD
Naproxen—Skin disorder—Epirubicin—bone cancer	8.42e-05	0.000536	CcSEcCtD
Naproxen—Hyperhidrosis—Epirubicin—bone cancer	8.38e-05	0.000533	CcSEcCtD
Naproxen—Insomnia—Methotrexate—bone cancer	8.38e-05	0.000533	CcSEcCtD
Naproxen—Arthralgia—Doxorubicin—bone cancer	8.37e-05	0.000533	CcSEcCtD
Naproxen—Chest pain—Doxorubicin—bone cancer	8.37e-05	0.000533	CcSEcCtD
Naproxen—Myalgia—Doxorubicin—bone cancer	8.37e-05	0.000533	CcSEcCtD
Naproxen—Anxiety—Doxorubicin—bone cancer	8.34e-05	0.000531	CcSEcCtD
Naproxen—Paraesthesia—Methotrexate—bone cancer	8.32e-05	0.000529	CcSEcCtD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	8.31e-05	0.000529	CcSEcCtD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	8.28e-05	0.00212	CbGpPWpGaD
Naproxen—Discomfort—Doxorubicin—bone cancer	8.27e-05	0.000526	CcSEcCtD
Naproxen—Anorexia—Epirubicin—bone cancer	8.26e-05	0.000526	CcSEcCtD
Naproxen—Dyspnoea—Methotrexate—bone cancer	8.26e-05	0.000526	CcSEcCtD
Naproxen—Somnolence—Methotrexate—bone cancer	8.23e-05	0.000524	CcSEcCtD
Naproxen—Dry mouth—Doxorubicin—bone cancer	8.18e-05	0.000521	CcSEcCtD
Naproxen—Dyspepsia—Methotrexate—bone cancer	8.15e-05	0.000519	CcSEcCtD
Naproxen—SLCO1A2—Metabolism—NDUFA12—bone cancer	8.13e-05	0.00209	CbGpPWpGaD
Naproxen—Hypotension—Epirubicin—bone cancer	8.1e-05	0.000516	CcSEcCtD
Naproxen—Confusional state—Doxorubicin—bone cancer	8.09e-05	0.000515	CcSEcCtD
Naproxen—Decreased appetite—Methotrexate—bone cancer	8.05e-05	0.000513	CcSEcCtD
Naproxen—Oedema—Doxorubicin—bone cancer	8.02e-05	0.000511	CcSEcCtD
Naproxen—Anaphylactic shock—Doxorubicin—bone cancer	8.02e-05	0.000511	CcSEcCtD
Naproxen—Gastrointestinal disorder—Methotrexate—bone cancer	8e-05	0.000509	CcSEcCtD
Naproxen—Fatigue—Methotrexate—bone cancer	7.99e-05	0.000508	CcSEcCtD
Naproxen—Infection—Doxorubicin—bone cancer	7.97e-05	0.000507	CcSEcCtD
Naproxen—CYP2C8—Arachidonic acid metabolism—PTGS2—bone cancer	7.94e-05	0.00204	CbGpPWpGaD
Naproxen—Pain—Methotrexate—bone cancer	7.92e-05	0.000504	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Epirubicin—bone cancer	7.9e-05	0.000503	CcSEcCtD
Naproxen—Shock—Doxorubicin—bone cancer	7.89e-05	0.000502	CcSEcCtD
Naproxen—Nervous system disorder—Doxorubicin—bone cancer	7.86e-05	0.000501	CcSEcCtD
Naproxen—Thrombocytopenia—Doxorubicin—bone cancer	7.85e-05	0.0005	CcSEcCtD
Naproxen—Insomnia—Epirubicin—bone cancer	7.84e-05	0.000499	CcSEcCtD
Naproxen—Tachycardia—Doxorubicin—bone cancer	7.83e-05	0.000498	CcSEcCtD
Naproxen—PTGS1—Selenium Micronutrient Network—PTGS2—bone cancer	7.82e-05	0.00201	CbGpPWpGaD
Naproxen—Skin disorder—Doxorubicin—bone cancer	7.79e-05	0.000496	CcSEcCtD
Naproxen—Paraesthesia—Epirubicin—bone cancer	7.78e-05	0.000495	CcSEcCtD
Naproxen—Hyperhidrosis—Doxorubicin—bone cancer	7.75e-05	0.000494	CcSEcCtD
Naproxen—UGT2B7—Metabolism—NT5C3A—bone cancer	7.74e-05	0.00199	CbGpPWpGaD
Naproxen—Dyspnoea—Epirubicin—bone cancer	7.73e-05	0.000492	CcSEcCtD
Naproxen—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—bone cancer	7.72e-05	0.00198	CbGpPWpGaD
Naproxen—Somnolence—Epirubicin—bone cancer	7.71e-05	0.00049	CcSEcCtD
Naproxen—Anorexia—Doxorubicin—bone cancer	7.64e-05	0.000487	CcSEcCtD
Naproxen—Feeling abnormal—Methotrexate—bone cancer	7.63e-05	0.000486	CcSEcCtD
Naproxen—Dyspepsia—Epirubicin—bone cancer	7.63e-05	0.000486	CcSEcCtD
Naproxen—UGT1A1—Metabolism—NDUFA12—bone cancer	7.59e-05	0.00195	CbGpPWpGaD
Naproxen—Gastrointestinal pain—Methotrexate—bone cancer	7.57e-05	0.000482	CcSEcCtD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	7.54e-05	0.00193	CbGpPWpGaD
Naproxen—Decreased appetite—Epirubicin—bone cancer	7.53e-05	0.00048	CcSEcCtD
Naproxen—Hypotension—Doxorubicin—bone cancer	7.49e-05	0.000477	CcSEcCtD
Naproxen—Gastrointestinal disorder—Epirubicin—bone cancer	7.48e-05	0.000476	CcSEcCtD
Naproxen—Fatigue—Epirubicin—bone cancer	7.47e-05	0.000476	CcSEcCtD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	7.43e-05	0.00191	CbGpPWpGaD
Naproxen—Pain—Epirubicin—bone cancer	7.41e-05	0.000472	CcSEcCtD
Naproxen—Constipation—Epirubicin—bone cancer	7.41e-05	0.000472	CcSEcCtD
Naproxen—PTGS2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	7.39e-05	0.0019	CbGpPWpGaD
Naproxen—Urticaria—Methotrexate—bone cancer	7.36e-05	0.000468	CcSEcCtD
Naproxen—Abdominal pain—Methotrexate—bone cancer	7.32e-05	0.000466	CcSEcCtD
Naproxen—Body temperature increased—Methotrexate—bone cancer	7.32e-05	0.000466	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Doxorubicin—bone cancer	7.31e-05	0.000465	CcSEcCtD
Naproxen—Insomnia—Doxorubicin—bone cancer	7.25e-05	0.000462	CcSEcCtD
Naproxen—Paraesthesia—Doxorubicin—bone cancer	7.2e-05	0.000458	CcSEcCtD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor—RB1—bone cancer	7.18e-05	0.00184	CbGpPWpGaD
Naproxen—Dyspnoea—Doxorubicin—bone cancer	7.15e-05	0.000455	CcSEcCtD
Naproxen—Feeling abnormal—Epirubicin—bone cancer	7.14e-05	0.000455	CcSEcCtD
Naproxen—Somnolence—Doxorubicin—bone cancer	7.13e-05	0.000454	CcSEcCtD
Naproxen—Gastrointestinal pain—Epirubicin—bone cancer	7.09e-05	0.000451	CcSEcCtD
Naproxen—Dyspepsia—Doxorubicin—bone cancer	7.06e-05	0.000449	CcSEcCtD
Naproxen—Decreased appetite—Doxorubicin—bone cancer	6.97e-05	0.000444	CcSEcCtD
Naproxen—Gastrointestinal disorder—Doxorubicin—bone cancer	6.92e-05	0.000441	CcSEcCtD
Naproxen—Fatigue—Doxorubicin—bone cancer	6.91e-05	0.00044	CcSEcCtD
Naproxen—Urticaria—Epirubicin—bone cancer	6.89e-05	0.000438	CcSEcCtD
Naproxen—PTGS2—Spinal Cord Injury—CDK4—bone cancer	6.87e-05	0.00176	CbGpPWpGaD
Naproxen—Constipation—Doxorubicin—bone cancer	6.86e-05	0.000437	CcSEcCtD
Naproxen—Pain—Doxorubicin—bone cancer	6.86e-05	0.000437	CcSEcCtD
Naproxen—Abdominal pain—Epirubicin—bone cancer	6.85e-05	0.000436	CcSEcCtD
Naproxen—Body temperature increased—Epirubicin—bone cancer	6.85e-05	0.000436	CcSEcCtD
Naproxen—Hypersensitivity—Methotrexate—bone cancer	6.82e-05	0.000434	CcSEcCtD
Naproxen—CYP1A2—Phase II conjugation—GSTP1—bone cancer	6.78e-05	0.00174	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—NT5C3A—bone cancer	6.74e-05	0.00173	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—RGS1—bone cancer	6.7e-05	0.00172	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—GRM4—bone cancer	6.7e-05	0.00172	CbGpPWpGaD
Naproxen—CYP2C8—Biological oxidations—CYP3A4—bone cancer	6.67e-05	0.00171	CbGpPWpGaD
Naproxen—Asthenia—Methotrexate—bone cancer	6.65e-05	0.000423	CcSEcCtD
Naproxen—Feeling abnormal—Doxorubicin—bone cancer	6.61e-05	0.000421	CcSEcCtD
Naproxen—CYP2C8—Metapathway biotransformation—CYP3A4—bone cancer	6.58e-05	0.00169	CbGpPWpGaD
Naproxen—Gastrointestinal pain—Doxorubicin—bone cancer	6.56e-05	0.000417	CcSEcCtD
Naproxen—Pruritus—Methotrexate—bone cancer	6.55e-05	0.000417	CcSEcCtD
Naproxen—ALB—Platelet activation, signaling and aggregation—SPARC—bone cancer	6.54e-05	0.00168	CbGpPWpGaD
Naproxen—CYP2C9—Arachidonic acid metabolism—PTGS2—bone cancer	6.46e-05	0.00166	CbGpPWpGaD
Naproxen—Hypersensitivity—Epirubicin—bone cancer	6.39e-05	0.000406	CcSEcCtD
Naproxen—Urticaria—Doxorubicin—bone cancer	6.37e-05	0.000406	CcSEcCtD
Naproxen—Abdominal pain—Doxorubicin—bone cancer	6.34e-05	0.000404	CcSEcCtD
Naproxen—Body temperature increased—Doxorubicin—bone cancer	6.34e-05	0.000404	CcSEcCtD
Naproxen—Diarrhoea—Methotrexate—bone cancer	6.34e-05	0.000403	CcSEcCtD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	6.3e-05	0.00162	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—NT5C3A—bone cancer	6.29e-05	0.00161	CbGpPWpGaD
Naproxen—Asthenia—Epirubicin—bone cancer	6.22e-05	0.000396	CcSEcCtD
Naproxen—PTGS1—Metabolism—NDUFA12—bone cancer	6.19e-05	0.00159	CbGpPWpGaD
Naproxen—AKR1C3—Disease—ENO2—bone cancer	6.16e-05	0.00158	CbGpPWpGaD
Naproxen—Pruritus—Epirubicin—bone cancer	6.13e-05	0.00039	CcSEcCtD
Naproxen—Dizziness—Methotrexate—bone cancer	6.12e-05	0.00039	CcSEcCtD
Naproxen—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	6.12e-05	0.00157	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—GNA11—bone cancer	5.98e-05	0.00154	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—RB1—bone cancer	5.97e-05	0.00153	CbGpPWpGaD
Naproxen—Diarrhoea—Epirubicin—bone cancer	5.93e-05	0.000378	CcSEcCtD
Naproxen—Hypersensitivity—Doxorubicin—bone cancer	5.91e-05	0.000376	CcSEcCtD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	5.9e-05	0.00152	CbGpPWpGaD
Naproxen—Vomiting—Methotrexate—bone cancer	5.89e-05	0.000375	CcSEcCtD
Naproxen—Rash—Methotrexate—bone cancer	5.84e-05	0.000372	CcSEcCtD
Naproxen—Dermatitis—Methotrexate—bone cancer	5.83e-05	0.000371	CcSEcCtD
Naproxen—AKR1C3—Signaling Pathways—GRM1—bone cancer	5.81e-05	0.00149	CbGpPWpGaD
Naproxen—Headache—Methotrexate—bone cancer	5.8e-05	0.000369	CcSEcCtD
Naproxen—Asthenia—Doxorubicin—bone cancer	5.75e-05	0.000366	CcSEcCtD
Naproxen—Dizziness—Epirubicin—bone cancer	5.73e-05	0.000365	CcSEcCtD
Naproxen—AKR1C3—Disease—DHFR—bone cancer	5.72e-05	0.00147	CbGpPWpGaD
Naproxen—CYP2C8—Biological oxidations—GSTP1—bone cancer	5.7e-05	0.00146	CbGpPWpGaD
Naproxen—Pruritus—Doxorubicin—bone cancer	5.67e-05	0.000361	CcSEcCtD
Naproxen—CYP2C8—Metapathway biotransformation—GSTP1—bone cancer	5.62e-05	0.00144	CbGpPWpGaD
Naproxen—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	5.52e-05	0.00142	CbGpPWpGaD
Naproxen—Vomiting—Epirubicin—bone cancer	5.51e-05	0.000351	CcSEcCtD
Naproxen—Nausea—Methotrexate—bone cancer	5.5e-05	0.00035	CcSEcCtD
Naproxen—Diarrhoea—Doxorubicin—bone cancer	5.49e-05	0.000349	CcSEcCtD
Naproxen—Rash—Epirubicin—bone cancer	5.46e-05	0.000348	CcSEcCtD
Naproxen—Dermatitis—Epirubicin—bone cancer	5.46e-05	0.000348	CcSEcCtD
Naproxen—Headache—Epirubicin—bone cancer	5.43e-05	0.000346	CcSEcCtD
Naproxen—CYP2C9—Biological oxidations—CYP3A4—bone cancer	5.43e-05	0.00139	CbGpPWpGaD
Naproxen—ALB—Platelet activation, signaling and aggregation—IL3—bone cancer	5.43e-05	0.00139	CbGpPWpGaD
Naproxen—CYP2C9—Metapathway biotransformation—CYP3A4—bone cancer	5.35e-05	0.00137	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	5.32e-05	0.00137	CbGpPWpGaD
Naproxen—Dizziness—Doxorubicin—bone cancer	5.3e-05	0.000338	CcSEcCtD
Naproxen—AKR1C3—Metabolism—ENO2—bone cancer	5.16e-05	0.00132	CbGpPWpGaD
Naproxen—Nausea—Epirubicin—bone cancer	5.15e-05	0.000328	CcSEcCtD
Naproxen—PTGS1—Metabolism—NT5C3A—bone cancer	5.13e-05	0.00132	CbGpPWpGaD
Naproxen—Vomiting—Doxorubicin—bone cancer	5.1e-05	0.000325	CcSEcCtD
Naproxen—ALB—Transmembrane transport of small molecules—TUBB4B—bone cancer	5.08e-05	0.00131	CbGpPWpGaD
Naproxen—Rash—Doxorubicin—bone cancer	5.06e-05	0.000322	CcSEcCtD
Naproxen—Dermatitis—Doxorubicin—bone cancer	5.05e-05	0.000322	CcSEcCtD
Naproxen—Headache—Doxorubicin—bone cancer	5.02e-05	0.00032	CcSEcCtD
Naproxen—ALB—Selenium Micronutrient Network—PTGS2—bone cancer	5.02e-05	0.00129	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—NDUFA12—bone cancer	4.91e-05	0.00126	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—DHFR—bone cancer	4.79e-05	0.00123	CbGpPWpGaD
Naproxen—Nausea—Doxorubicin—bone cancer	4.76e-05	0.000303	CcSEcCtD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	4.67e-05	0.0012	CbGpPWpGaD
Naproxen—CYP2C9—Biological oxidations—GSTP1—bone cancer	4.64e-05	0.00119	CbGpPWpGaD
Naproxen—CYP1A2—Biological oxidations—CYP3A4—bone cancer	4.64e-05	0.00119	CbGpPWpGaD
Naproxen—CYP2C9—Metapathway biotransformation—GSTP1—bone cancer	4.58e-05	0.00118	CbGpPWpGaD
Naproxen—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	4.57e-05	0.00117	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—GNA11—bone cancer	4.47e-05	0.00115	CbGpPWpGaD
Naproxen—ALB—Transmembrane transport of small molecules—TUBB2A—bone cancer	4.39e-05	0.00113	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—MMP9—bone cancer	4.31e-05	0.00111	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	4.18e-05	0.00107	CbGpPWpGaD
Naproxen—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	4.18e-05	0.00107	CbGpPWpGaD
Naproxen—AKR1C3—Disease—TGFBR2—bone cancer	4.14e-05	0.00106	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—SMO—bone cancer	4.09e-05	0.00105	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—NT5C3A—bone cancer	4.07e-05	0.00105	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—CYP3A4—bone cancer	4.06e-05	0.00104	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	4.04e-05	0.00104	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—NDUFA12—bone cancer	4e-05	0.00103	CbGpPWpGaD
Naproxen—ALB—Metabolism—NDUFA12—bone cancer	3.97e-05	0.00102	CbGpPWpGaD
Naproxen—CYP1A2—Biological oxidations—GSTP1—bone cancer	3.97e-05	0.00102	CbGpPWpGaD
Naproxen—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	3.91e-05	0.001	CbGpPWpGaD
Naproxen—ALB—Folate Metabolism—TP53—bone cancer	3.76e-05	0.000966	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—GNA11—bone cancer	3.74e-05	0.00096	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—EGFR—bone cancer	3.48e-05	0.000893	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—ATF1—bone cancer	3.48e-05	0.000893	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—GSTP1—bone cancer	3.47e-05	0.000891	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	3.46e-05	0.000889	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—IL3—bone cancer	3.39e-05	0.000871	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—ENO2—bone cancer	3.39e-05	0.00087	CbGpPWpGaD
Naproxen—ALB—Hemostasis—SPARC—bone cancer	3.37e-05	0.000866	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—NT5C3A—bone cancer	3.31e-05	0.00085	CbGpPWpGaD
Naproxen—ALB—Metabolism—NT5C3A—bone cancer	3.29e-05	0.000845	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—NDUFA12—bone cancer	3.25e-05	0.000835	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—DHFR—bone cancer	3.15e-05	0.000808	CbGpPWpGaD
Naproxen—ALB—Hemostasis—GNA11—bone cancer	3.08e-05	0.000792	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	3.01e-05	0.000773	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—ENO2—bone cancer	2.95e-05	0.000758	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—GNA11—bone cancer	2.94e-05	0.000755	CbGpPWpGaD
Naproxen—PTGS2—Spinal Cord Injury—TP53—bone cancer	2.92e-05	0.00075	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—TGFBR2—bone cancer	2.9e-05	0.000745	CbGpPWpGaD
Naproxen—AKR1C3—Disease—KIT—bone cancer	2.83e-05	0.000726	CbGpPWpGaD
Naproxen—ALB—Hemostasis—IL3—bone cancer	2.8e-05	0.000718	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—NDUFA12—bone cancer	2.78e-05	0.000714	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—ENO2—bone cancer	2.76e-05	0.000707	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—DHFR—bone cancer	2.74e-05	0.000703	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—IGF1R—bone cancer	2.73e-05	0.000701	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—NT5C3A—bone cancer	2.7e-05	0.000692	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—CYP3A4—bone cancer	2.67e-05	0.000684	CbGpPWpGaD
Naproxen—AKR1C3—Disease—BRAF—bone cancer	2.66e-05	0.000682	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—GNA11—bone cancer	2.56e-05	0.000657	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—DHFR—bone cancer	2.56e-05	0.000656	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—GNA11—bone cancer	2.39e-05	0.000613	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	2.37e-05	0.000608	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—CYP3A4—bone cancer	2.32e-05	0.000596	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.31e-05	0.000593	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—NT5C3A—bone cancer	2.3e-05	0.000591	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—GSTP1—bone cancer	2.28e-05	0.000585	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—ENO2—bone cancer	2.25e-05	0.000577	CbGpPWpGaD
Naproxen—AKR1C3—Disease—MDM2—bone cancer	2.23e-05	0.000571	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—CYP3A4—bone cancer	2.17e-05	0.000556	CbGpPWpGaD
Naproxen—AKR1C3—Disease—PTGS2—bone cancer	2.15e-05	0.000551	CbGpPWpGaD
Naproxen—PTGS2—Disease—ENO2—bone cancer	2.13e-05	0.000547	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—DHFR—bone cancer	2.08e-05	0.000535	CbGpPWpGaD
Naproxen—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	1.99e-05	0.00051	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—GSTP1—bone cancer	1.98e-05	0.00051	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—KIT—bone cancer	1.98e-05	0.000508	CbGpPWpGaD
Naproxen—PTGS2—Disease—DHFR—bone cancer	1.98e-05	0.000507	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—GNA11—bone cancer	1.95e-05	0.0005	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—BRAF—bone cancer	1.86e-05	0.000478	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—GSTP1—bone cancer	1.85e-05	0.000476	CbGpPWpGaD
Naproxen—ALB—Hemostasis—PLAU—bone cancer	1.83e-05	0.000471	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—PTGS2—bone cancer	1.8e-05	0.000461	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—ENO2—bone cancer	1.78e-05	0.000458	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—CYP3A4—bone cancer	1.77e-05	0.000453	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.76e-05	0.000451	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—DHFR—bone cancer	1.65e-05	0.000425	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—MDM2—bone cancer	1.56e-05	0.0004	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—GNA11—bone cancer	1.55e-05	0.000397	CbGpPWpGaD
Naproxen—AKR1C3—Disease—EGFR—bone cancer	1.52e-05	0.000391	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—GSTP1—bone cancer	1.51e-05	0.000388	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—ENO2—bone cancer	1.45e-05	0.000372	CbGpPWpGaD
Naproxen—ALB—Metabolism—ENO2—bone cancer	1.44e-05	0.00037	CbGpPWpGaD
Naproxen—PTGS2—Disease—TGFBR2—bone cancer	1.43e-05	0.000367	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—CYP3A4—bone cancer	1.4e-05	0.00036	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—JUN—bone cancer	1.35e-05	0.000348	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—DHFR—bone cancer	1.35e-05	0.000346	CbGpPWpGaD
Naproxen—ALB—Metabolism—DHFR—bone cancer	1.34e-05	0.000344	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—MMP9—bone cancer	1.32e-05	0.000338	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—GNA11—bone cancer	1.26e-05	0.000323	CbGpPWpGaD
Naproxen—ALB—Metabolism—GNA11—bone cancer	1.25e-05	0.000321	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—GSTP1—bone cancer	1.2e-05	0.000308	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—PTGS2—bone cancer	1.18e-05	0.000303	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—ENO2—bone cancer	1.18e-05	0.000303	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—CYP3A4—bone cancer	1.14e-05	0.000293	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.13e-05	0.000291	CbGpPWpGaD
Naproxen—ALB—Metabolism—CYP3A4—bone cancer	1.13e-05	0.000291	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.13e-05	0.00029	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—DHFR—bone cancer	1.1e-05	0.000281	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—EGFR—bone cancer	1.07e-05	0.000273	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PTGS2—bone cancer	1.03e-05	0.000264	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—GNA11—bone cancer	1.02e-05	0.000263	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ENO2—bone cancer	1.01e-05	0.000259	CbGpPWpGaD
Naproxen—PTGS2—Disease—KIT—bone cancer	9.77e-06	0.000251	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—GSTP1—bone cancer	9.75e-06	0.00025	CbGpPWpGaD
Naproxen—ALB—Metabolism—GSTP1—bone cancer	9.7e-06	0.000249	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PTGS2—bone cancer	9.6e-06	0.000246	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—DHFR—bone cancer	9.36e-06	0.00024	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—CYP3A4—bone cancer	9.28e-06	0.000238	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	9.23e-06	0.000237	CbGpPWpGaD
Naproxen—PTGS2—Disease—BRAF—bone cancer	9.18e-06	0.000236	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—TP53—bone cancer	8.94e-06	0.00023	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—GNA11—bone cancer	8.75e-06	0.000225	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—GSTP1—bone cancer	7.94e-06	0.000204	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CYP3A4—bone cancer	7.93e-06	0.000204	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	7.89e-06	0.000203	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PTGS2—bone cancer	7.82e-06	0.000201	CbGpPWpGaD
Naproxen—PTGS2—Disease—MDM2—bone cancer	7.69e-06	0.000197	CbGpPWpGaD
Naproxen—ALB—Hemostasis—TP53—bone cancer	7.38e-06	0.000189	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—GSTP1—bone cancer	6.78e-06	0.000174	CbGpPWpGaD
Naproxen—PTGS2—Disease—EGFR—bone cancer	5.26e-06	0.000135	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PTGS2—bone cancer	5.05e-06	0.00013	CbGpPWpGaD
Naproxen—ALB—Metabolism—PTGS2—bone cancer	5.02e-06	0.000129	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PTGS2—bone cancer	4.11e-06	0.000106	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PTGS2—bone cancer	3.51e-06	9.02e-05	CbGpPWpGaD
